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Although vulval SCC is less common than cervical cancer, it is of
major mechanistic interest since cancers are either HPV positive
(principally HPV 16) or lack detectable HPV DNA sequences.
HPV-positive cancers have an association with vulval intraepithe-
lial neoplasia (VIN) (reviewed by Crum, 1992). Clear pathobio-
logical differences between HPV-positive and HPV-negative
cancers have been described (Crum, 1992). Allelotype analysis
has revealed that no significant differences in sites of loss of
heterozygosity (LOH) exist between the 2 forms of the disease
(Pinto et al, 1999). However, a number of studies have revealed
that mutation in p53 is more common in HPV-negative cancers
(Lee et al, 1994; Marin et al, 2000; Brooks et al, 2001). Mechan-
istically, it is hypothesised that mutation in p53 functionally
compensates for the absence of HPV 16E6, since this protein
mediates inactivation of p53 via promotion of ubiquitin-dependent
proteolysis. Despite the more common mutation of p53 in HPV-
negative cases, a substantial number of vulval SCC occur which
lack both mutation and HPV. The mechanism, if any, by which p53
function may be compromised in such cases is not known. 
p73 has structural and functional homologies to p53, including
sequence-specific DNA binding and transactivation functions
(Kaghad et al, 1997). Over-expression of p73 is able to induce
apoptosis in some human cancer lines (Jost et al, 1997) and
expression of p73 has been shown to have a role in the differentia-
tion of keratinocytes (De Laurenzi et al, 2000). p73 is expressed as
a number of isoforms which arise by alternative splicing of exons
encoding the –COOH terminus of the protein and which exhibit
differences in trans-activating and growth suppressor functions
(De Laurenzi et al, 1998; Ueda et al, 1999). The expression of a
further spliced variant of p73 which lacks exon 2 (p73 ∆ 2) has
been described in ovarian cancer (Ng et al, 2000) and in breast
cancer cell lines (Fillippovich et al, 2001). Recently, p73 has been
shown to be directly induced by E2F-1 and thereby to contribute to
E2F-1-mediated apoptosis (Irwin et al, 2000; Lissy et al, 2000).
Furthermore, both myc and adenovirus E1A can activate expres-
sion of p73 (Zaika et al, 2000). 
Although p73 is subject to methylation-dependent transcriptional
silencing in some B-cell malignancies, consistent with a role as a
putative tumour-suppressor protein (Corn et al, 1999), mutational
analyses have suggested that neither p63 nor p73 is frequently
mutated in human cancers (Yoshikawa et al, 1999). Furthermore,
p73 is over-expressed in some cancers, although the mechanism of
this is unknown (Chi et al, 1999; Zaika et al, 1999). Assessment of
the biological significance of the ability of p73 ∆ 2 to transdomi-
nantly inhibit both p53 and full-length p73 clearly requires analysis
of the expression of this variant in a range of both normal and malig-
nant tissues (Fillippovich et al, 2001). In the current study we have
investigated the structure and expression of p73 in vulval neoplasia. 
MATERIALS AND METHODS 
Tissues 
SCC of the vulva and VIN III tissue samples were collected at 
operation. In each case the diagnosis was confirmed by routine
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immediately into liquid nitrogen and stored until isolation of nucleic
acids. Genomic DNA was isolated by proteinase K digestion and
total RNA by RNAzol B. Cancers and VIN III were HPV-typed
using standard PCR methodology. Paraffin sections of vulval
neoplasia were retrieved from the Department of Histopathology at
St Mary’s Hospital, Paddington, London. 
Analysis of gene expression 
cDNA was synthesised with the ProStar system (Stratagene) from
3 µ g of total RNA. Analysis of expression was performed by RT-
PCR as described previously for p14ARF (Gazzeri et al, 1998), and
p73 (De Laurenzi et al, 1998). For semi-quantitative analysis of
gene expression, PCR was performed using the primers and
thermal cycling conditions described and was for 22 cycles for
p14ARF, and 28 cycles for p73. In some experiments, amplification
was extended to 40 cycles to analyse expression in tissues
expressing a lower level of p73. Following PCR, reactions were
resolved on agarose gels, transferred to Hybond-N+ nylon and
hybridised with 32P γ -ATP-labelled oligonucleotide probes specific
for the amplified fragments. Analysis of N-terminal splice variants
of p73 was performed using the primers described by Ng et al
(2000). Identity of these was confirmed by cloning and sequencing
and by hybridisation analysis of amplified products with oligo-
nucleotide probes specific for exon 2 and exon 3 of p73. The pres-
ence of equivalent amounts of cDNA in each PCR was verified by
amplification of β -actin under similar limiting conditions. RT-PCR
analysis of p16INK4a was performed as described previously
(Gonzalez-Zulueta et al, 1995). 
Immunocytochemistry 
5 µ m sections were cut from formalin-fixed, paraffin-embedded,
tissue sections. The diagnosis in each case was confirmed by
examination of haematoxylin and eosin-stained sections. For
immunocytochemistry, sections were pressure-cooked in citrate
buffer, then stained with antibodies: p14ARF goat polyclonal ((C20)
Santa Cruz, SC-8613) was used at 1/100 dilution; p73 mouse
monoclonal antibody Neomarkers, MS-764-P0, affinity-purified
and diluted 1/150. Sections were scored independently by at least
2 pathologists. To demonstrate increase in p73 expression with
increasing grade of neoplasia, sections were scored according to
the following scheme. 1: basal staining only; 2: suprabasal staining
where less than 50% of nuclei were positive in the strongest
staining area in a high power field; 3: suprabasal staining where
greater than 50% of nuclei were positive in the strongest stained
area in a high-power field. 
Analysis of gene structure 
Mutations in exon 1α and 2 of the INK4 locus were sought using
single-strand conformation polymorphism analysis (SSCP) with
primers and PCR conditions described by Zhang et al (1994). PCR
reactions were resolved on 6% native acrylamide gels with and
without 5% glycerol. Methylation of CpG sequences in the
p16INK4a promoter was performed using methylation-specific PCR
(MSP) as described by Herman et al (1996). To examine exon 1β
for mutations, SSCP was performed using cDNA as the substrate
and resolution on 6% gels as described above (Gazzeri et al,
1998). cDNA prepared from the Burkitt’s lymphoma cell line
Mutu was used as a positive control. Analysis of p73 coding
sequences in the regions corresponding to the mutational hot spots
of p53 was done by RT-PCR SSCP using conditions described by
Kawano et al (1999). 
RESULTS 
Wild-type p73 is frequently over-expressed in vulval
neoplasia 
The expression of p73 was investigated in a series of vulval SCC and
in VIN, previously analysed for the presence of HPV DNA
sequences. In initial experiments, expression was analysed using RT-
PCR methodology (De Laurenzi et al, 1998). This assay allows
discrimination between alternatively spliced forms encoding
different –COOH variants of p73 protein. Expression of p73 mRNA
was detectable by RT-PCR in each of the 36 normal vulval epithelial
samples available for analysis using 40 cycles of amplification.
Expression was predominantly of α and γ variants in each of the
normal vulval samples analysed. In cancers, expression was also
restricted to the α and γ forms, but using limiting PCR conditions,
was markedly increased relative to matched normal vulval epithe-
lium in 29/36 cases examined (Figure 1). Interestingly, over-
expression of p73 mRNA was detected in cancers both positive and
negative for HPV DNA (Table 1A). To confirm that the elevated p73
mRNA levels were reflected in protein expression and to investigate
possible associations between p73 expression and grade of neoplasia,
we performed immunocytochemical analysis of tissue sections of
VIN and SCC cut from paraffin blocks. These studies revealed that
expression of p73 was detectable in each case of normal epithelium,
consistent with RT-PCR analysis performed under extended cycling
conditions (Figure 2). Expression was restricted to the basal and
supra-basal layers in normal tissue, but this restriction was lost with
increasing grade (Figure 2). To further demonstrate the increase in
expression with grade of neoplasia, expression was scored using a
semi-quantitative immunocytochemical technique in VIN. A mean
expression index was calculated for each of VIN I, VIN II and VIN
III. This clearly demonstrated the increase in expression from VIN I
to VIN III (Table 1B). The presence of mutations in the over-
expressed p73 mRNA was sought using RT-SSCP (Kawano et al,
1999). No mobility shifts suggestive of mutation were detected in 24
vulval SCC analysed. 
p73 ∆ 2 is the predominant over-expressed form of p73 
The high frequency of over-expression of p73α and γ in vulval
SCC, in the absence of mutations, was unexpected in view of the
pro-apoptotic and negative growth-regulatory functions of these
proteins. We therefore performed additional RT-PCR analysis to
examine the N-termini of the mRNA species. There was over-
expression of p73 ∆ 2 in the majority of vulval SCC shown to
over-express p73α (Figure 1 and Table 1A). Full-length p73 was
only rarely simultaneously over-expressed, p73 ∆ 2 being the
only form expressed in the majority of cases (Figure 1 and
Table 1A). 
Inactivation of p16INK4a correlates inversely with the
presence of HPV 
The ability of HPV E7 to deregulate p73 expression via E2F-1
and pRb provides a mechanistic explanation for over-expression
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alternative mechanisms by which pRb function might be inhibited,
to determine how p73 was deregulated in cases lacking HPV. To
address this issue, we analysed the structure and expression of
p16INK4a to determine whether mutation and/or epigenetic
silencing of the gene was related to deregulation of p73 in 
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Figure 1 (A) p73 expression in vulval neoplasia. RT-PCR analysis of p73 expression in paired normal (N) and tumour (T). PCR was performed for 28 cycles.
p73 is predominantly expressed as the α and γ isoforms (upper and lower arrows respectively). The middle panel shows that expression of p14ARF is
deregulated with p73 in a subset of vulval SCC. Cancers T3, T4, T5 and T6 which do not have deregulated p14ARF lack HPV DNA and mutant p53. The lower
panel is actin. (B) Expression of p73 in vulval neoplasia can be deregulated in the presence of either HPV DNA or transcriptional silencing of p16INK4a. T1 and T2
(each with matched normal N1 and N2) are HPV positive vulval SCC and over-express p16INK4a mRNA. T3 and T4 (also with matched normal) are vulval SCC
with hypermethylated p16INK4a sequences and concomitant absence of p16 transcript. p73 RNA is over-expressed in both groups of cancer. PCR was performed
for 28 cycles for both p73 and p16INK4a. (C) Vulval cancers over-express p73 ∆ 2. T1 is a vulval SCC which over-expresses both full-length and ∆ 2 forms,
whereas T5 and T6 express only the ∆ 2 form. V3 and V4 are VIN I and do not express detectable p73 RNA under these limiting PCR conditions (28 cycles of
PCR). Note also the absence of detectable p73mRNA in each matched normal (N1–N6) under these conditions 
Figure 2 Immunocytochemical analysis of expression of p73 in normal and neoplastic vulval epithelium. Sections were prepared from formalin-fixed, parrafin-
embedded tissue samples as described in Materials and Methods.(A) Expression of p73 in normal vulval epithelium is in the basal and immediately supra-basal
cells. RT-PCR showed that this was predominantly p73α and p73γ . (B) Expression of p73 in VIN II 
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CHPV negative cases. Using MSP, the presence of hypermethyla-
tion in the p16INK4a gene promoter was detected in 13/36 cases
of vulval SCC (Figure 3, Table 1A). Mutations in p16INK4a
were detected in 3/36 vulval SCC (Figure 4), all 3 cases
being HPV-negative. No mutations were detected in p16INK4a in 21
HPV16-positive vulval SCC or in 78 HPV16-positive cervical
SCC. Taken together, of the 16 cases of vulval SCC with inactiva-
tion of p16INK4a, only one was HPV16-positive. Over-expression of
p73 occurred in 15/16 cases of HPV-negative vulval SCC with
p16INK4a inactivation (Table 1A, Figure 1). These data imply that
inactivation of p16INK4a and expression of HPV16 E7 may be func-
tionally interchangeable events in vulval neoplasia and that either
can result in p73 over-expression.
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Figure 3 MSP analysis of CpG methylation in the p16INK4a gene promoter in
vulval neoplasia. Each paired lane represents either methylated (M) or
unmethylated (U) DNA for each vulval SCC. Note the presence of
methylated DNA in cancers 3 and 5. The presence of unmethylated DNA in
both cases is attributable either to the presence of normal tissue within the
tumour biopsy or hemimethylation of the CpG sequences. M = DNA
molecular weight markers 
Table 1A Expression of p14, p16 and p73 in vulval cancers 
Cancer p53  status  HPV  p16INK4a RNA p16INK4a meth. FL  p73  p73∆ 2 p14ARF
1 Mt  –  – Yes –   +  + 
2 Mt  –  – Yes – +  + 
3 Mt  –  –   Yes  +  +  + 
4 Mt  –  –  –   +  +  + 
5 Mt  –  –  –  –   +  + 
6 Mt  –  – Yes –   +  – 
7 Mt  –  – Yes –   +  –
8 Mt  – +  –  –   –  – 
9 Mt  –  – Yes –   +  + 
10 Mt  –  – Yes –   – + 
11 Mt  –  –  –  –   –  – 
12 Mt  16 +  –   +  +  + 
13 Mt  –  – Yes –   – + 
14 Mt  16 +  –   +  +  + 
15 Mt  –  –  –  –   – + 
16 Mt  –  –  –  –   – + 
17 Mt  – Mta –  –   +  + 
18 Mt  –  – Yes –   +  – 
19 Mt  – +  –  –   +  + 
20 Mt  16 +  –  –   +  + 
21 Mt  16 +  –  –   +  + 
22 Wt  16 +  –  –   +  + 
23 Wt  –  –  –   +  +  + 
24 Wt  16 +  –  –   +  + 
25 Wt  16 +  –  –   +  + 
26 Wt  – +  –  –   –  – 
27 Wt  16 +  –   +  +  + 
28 Wt  16 +  –  –   +  + 
29 Wt  16 +  –   – +  + 
30 Wt  –  – Yes –   +  – 
31 Wt  –  – Yes –   +  – 
32 Wt  16 +  –  –   +  + 
33 Wt  – Mtb –  –   +  – 
34 Wt  16 +  Yes  –   +  – 
35 Wt  – Mtc –  –   +  – 
36 Wt  16 – Yes –   +  + 
Expression was determined by RT-PCR as described in Methods and Materials. Mt = mutant, Wt = wild-type. FL p73 = full-length p73.
∆ 2 p73 = deleted exon 2 p73. + denotes expression of p73 and p14ARF increased relative to matched normal tissue. + denotes detectable
expression of p16INK4a. The mutations in p16INK4a are: acodon 80 Cga >TgA = Arg >Ter; bcodon 11 CCT > CTT = Pro > Leu; ccodon 48
CCg >TCg = Pro > Ser. The polymorphism at codon 148 Ala > Thr was detected in 4/36 individuals analysed. 
Table 1B Effect of grade of neoplasia on expression of p73 
VIN I  VIN II  VIN III  SCC 
Mean score  1.2 +/– 0.46  1.42+/– 0.37  2.25 +/–0.68 2.59+/–0.44 
Data shown are staining indices, determined as described in Methods, +/– standard deviation. p73 expression is deregulated with p14ARF in cancers
with loss of p53 function 
Because p73 is deregulated by E2F-1 expression (Irwin et al, 2000;
Lissy et al, 2000), we determined the expression levels of another
recognised E2F-1 regulated gene, p14ARF (Bates et al, 1998), in
cancers with p73 over-expression. Using RT-PCR, we determined
whether p73 and p14ARF were over-expressed together in vulval
cancers either positive for HPV, mutant for p53 or having neither
(Figure 1). 29/36 vulval SCC analysed by RT-PCR over-expressed
p73 and there was concomittant over-expression of p14ARF in
21/29. Of these, 20 cases were either mutant for p53 or positive for
HPV 16. In total, 6 vulval SCC were both negative for HPV and
contained wild-type p53 sequence. Of these 6 cases, p73 was over-
expressed in 5, but p14ARF in only a single case. These results
suggest that deregulation of p14ARF, but not p73, requires loss of
p53 function. 
DISCUSSION 
In this work we show that expression of p73 is deregulated at both
protein and mRNA levels in a high proportion of vulval carci-
nomas and pre-malignant lesions. Our results are consistent with
studies which have reported over-expression of p73 in other
common cancers, including breast (Zaika et al, 1998), bladder (Chi
et al, 1999) and hepatocellular carcinoma (Tannapfel et al, 1999).
We also make the important observation that deregulation is
frequently of the ∆ 2 transdominant form of p73. 
p73 exists as a number of isoforms, generated by alternative
splicing of exons encoding the -COOH terminus of the protein
(De Laurenzi et al, 1998; Ueda et al, 1999). Multiple isoforms
are expressed in keratinocytes (De Laurenzi et al, 1998). In
cervical epithelium the α form is the overwhelmingly predomi-
nant variant expressed (data not shown). It is of interest, there-
fore, that p73 expression is predominantly of the α and γ forms in
vulval epithelium. It is also noteworthy that whereas expression
of p73 is restricted to the basal and supra-basal layers in normal
epithelium, this restriction is lost in VIN and in SCC, expression
frequently encompassing the entire epithelium. A further observa-
tion of interest was the increase in expression with increasing
grade of neoplasia. Over-expression of p73 protein has been corre-
lated with progression of other cancers, for example in the bladder,
where p73-positive cancers are associated with poor prognosis
(Tannapfel et al, 1999). 
In view of the hypothesised role of p73 as a tumour-suppressor
protein, it was perhaps surprising to observe over-expression in
such a high proportion of cases. Sequence analysis did not detect
mutations in p73 in vulval cancers, findings consistent with other
authors’ studies of both solid and haematological malignancies
(Yoshikawa et al, 1999). A variant of p73 which excludes exon 2
(p73 ∆ 2) was recently described in ovarian carcinomas (Ng et al,
2000) and in some breast cancer cell lines (Filippovich et al,
2001). The authors of the latter study stressed the importance of
analysing expression of the ∆ 2 form in a range of normal and
malignant tissues. In the present study, we make the interesting
observation that, in vulval cancer, p73 over-expression is indeed
predominantly of the ∆ 2 form, and in some cases in our series this
was the only form of p73 detectable. p73 ∆ 2 has been shown to
inhibit the transactivating function of both p53 and full-length p73
(Filippovich et al, 2001). As such, the over-expression of p73 ∆ 2
forms suggests a contribution to tumourigenesis in vulval SCC
by transdominant inhibition of wild-type p53 and full-length p73.
It is also an interesting possibility that over-expression of p73∆ 2
may be related to the differentiation status of squamous cancers.
The importance of full-length p73 expression in mediating
keratinocyte differentiation has been clearly demonstrated
(De Laurenzi et al, 2000). It is, therefore, an attractive hypothesis
that impaired differentiation of some squamous cancers may, at
least in part, result from transdominant inhibition of full-length
p73-dependent differentiation by the ∆ 2 variant. Additional
studies to address this hypothesis would clearly be of interest. 
Expression of p73 is driven by E2F-1 (Irwin et al, 2000; Lissy
et al, 2000). It was therefore of interest to investigate potential
mechanisms by which E2F-1 is itself deregulated in vulval cancer.
A subset of the SCC contained and expressed HPV 16 DNA
sequences. HPV16 E7 associates with pRb and thereby deregu-
lates expression of E2F-1 responsive genes such as B-myb (Lam
et al, 1994), providing a mechanistic explanation for p73 deregu-
lation in HPV-positive cases. Analysis of HPV-negative cases
revealed frequent abnormalities in p16INK4a, either in the form
of point mutations or methylation-dependent transcriptional
silencing. Inactivation of p16INK4a was inversely correlated with the
presence of HPV DNA in the majority of cases, implying that loss
of p16INK4a function can, at least partially, compensate for the
absence of HPV E7 expression. Support for this hypothesis is
afforded by the consistent absence of p16INK4a mutations in a large
series of HPV-positive cervical SCC, whereas mutations in
p16INK4a were detected in 3/16 HPV-negative vulval SCC. 
Support for the hypothesis that over-expression of p73 results
from E2F-1 deregulation was provided by the observation of co-
ordinate over-expression with p14ARF in a large proportion of
vulval cancers with simultaneous loss of p53 function (via muta-
tion or HPV 16 positivity). Interestingly, vulval cancers lacking a
p53 mutation and HPV 16 did not, in general, over-express p14ARF
despite frequent, abundant over-expression of p73. Previous
studies have revealed that cells over-expressing p14ARF are almost
always null for p53 (Stott et al, 1998). Our data are consistent with
this hypothesis and also suggest that deregulation of p73 is not
dependent on the p53 status of the cell. 
In conclusion, our results add to the growing evidence that p73
over-expression is a common event in human neoplasia and
provide direct support from clinical biopsy material for E2F 
1-driven p73 deregulation in vivo. 
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Figure 4 Mutations occur in exon 2 of p16INK4a in vulval but not cervical
SCC. The autoradiographs show SSCP analysis of exon 2 of INK4 in
anogenital neoplasia. (A) 5′ portion of exon 2. Lanes 1–8 are cervical SCC.
Lane 9 is vulval cancer with mutation. (B) 3′ portion of exon 2. Lanes 1–9 are
cervical SCC. Lanes 10 and 11 are vulval SCC, each with polymorphism at
codon 148 of p16INK4a. The abnormal mobility bands are indicated by arrows 
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